BYSI NASDAQ
BeyondSpring Inc.
1W: +1.3%
1M: +28.9%
3M: -56.0%
YTD: -51.1%
1Y: -56.0%
3Y: +5.0%
5Y: -94.9%
$0.79
-0.03 (-3.24%)
Weekly Expected Move ±30.2%
$0
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (15)
BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis
BeyondSpring GAAP EPS of -$0.02
BeyondSpring Reports Second-Quarter 2026 Financial Results and Provides Corporate Update
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
BeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC Drugs
BeyondSpring (NASDAQ:BYSI) Stock Passes Above 50 Day Moving Average – Here’s Why
BeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026
BeyondSpring GAAP EPS of -$0.21
BeyondSpring Reports 2025 Year-End Financial Results
BeyondSpring Reports 2025 Year-End Financial Results
12 Health Care Stocks Moving In Tuesday's Intraday Session
BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference
Financial Contrast: Lisata Therapeutics (NASDAQ:LSTA) vs. BeyondSpring (NASDAQ:BYSI)
Critical Review: Cyclerion Therapeutics (NASDAQ:CYCN) & BeyondSpring (NASDAQ:BYSI)
BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path